-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, NF7bba9DiQyqmWG5WFsvQHHkFvzgmIV6fKB+8FzvcgSOzohA9mrasDQO4O0V8T4Z UKjgpB/wJVmZWOy+GEVLnQ== 0000946644-04-000008.txt : 20040422 0000946644-04-000008.hdr.sgml : 20040422 20040422150132 ACCESSION NUMBER: 0000946644-04-000008 CONFORMED SUBMISSION TYPE: POS AM PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040422 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HEMISPHERX BIOPHARMA INC CENTRAL INDEX KEY: 0000946644 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 520845822 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: POS AM SEC ACT: 1933 Act SEC FILE NUMBER: 333-102513 FILM NUMBER: 04747994 BUSINESS ADDRESS: STREET 1: 1617 JFK BLVD #660 STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 2159880080 MAIL ADDRESS: STREET 1: 1617 JFK BLVD STREET 2: ONE PENN CENTER CITY: PHILADELPHIA STATE: PA ZIP: 19103 POS AM 1 rpos-am.txt As filed with the Securities and Exchange Commission on April 22, 2004 Registration No. 333- SEC File No 333-102513 - ------------------------------------------------------------------------------- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 -------------------- HEMISPHERX BIOPHARMA, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 52-0845822 (I.R.S. Employer Identification No.) -------------------- 1617 JFK Boulevard Philadelphia, Pennsylvania 19103 (215) 988-0080 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) -- William A. Carter, M.D., Chief Executive Officer Hemispherx Biopharma, Inc. 1617 JFK Boulevard Philadelphia, Pennsylvania 19103 (215) 988-0080 (Name, address, including zip code, and telephone number, including area code, of agent for service) Copies of all communications to: Richard Feiner, Esq. Silverman Sclar Shin & Byrne PLLC 381 Park Avenue South, Suite 1601 New York, New York, 10016 (212) 779-8600 Fax (212) 779-8600 Approximate date of proposed sale to the public: Not Applicable. If the only securities being registered on this form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. [ ] If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 ("Securities Act"), other than securities offered only in connection with dividend or reinvestment plans, check the following box. [ ] If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [ ] If this form is a post-effective amendment filed pursuant to 462(c) under the Securities Act, check the following box and list the Securities Act registration number of the earlier effective registration statement for the same offering.[ ] If delivery of the prospectus is expected to be made pursuant to Rule 434, please check the following box. [ ] The registrant hereby deregisters all of the securities of the registrant previously registered in the original Registration Statement on Form S-3 filed with the Commission on January 14, 2003. These securities consisted of 499,996 warrants to purchase shares of our common stock and 5,499,996 shares of our common stock. No securities were sold pursuant to the Registration Statement. The registrant is using Form S-1 because it does not currently meet all of the requirements for use of Form S-3. SIGNATURES Pursuant to the requirement of the Securities Act of 1933, the Registrant has duly caused this Post-Effective Amendment No. 1 to its Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Philadelphia, Commonwealth of Pennsylvania, on the 22th day of April, 2004. HEMISPHERX BIOPHARMA, INC. (Registrant) By: /s/ William A. Carter ---------------------- William A. Carter, M.D., Chief Executive Officer Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated. Signature Title Date - --------- -------- --------------- /s/ William A. Carter Chairman of the Board, April 22, 2004 - --------------------- Chief Executive Officer William A. Carter, M.D. (Principal Executive) and Director Richard Piani* Director April 22, 2004 Robert E. Peterson* Chief Financial Officer and April 22, 2004 Chief Accounting Officer Ransom Etheridge* Secretary And Director April 22, 2004 William Mitchell, M.D., Ph.D.* Director April 22, 2004 Iraj-Eqhbal Kiani, M.D. Director * By: /s/ Wlliam A. Carter -------------------- William A. Carter, M.D., Attorney-in-Fact -----END PRIVACY-ENHANCED MESSAGE-----